Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 18, 2003, Pages 3049-3053

  Zhang, Han Cheng ^a   White, Kimberly B ^a   Ye, Hong ^a   McComsey, David F ^a   Derian, Claudia K ^a   Addo, Michael F ^a   Andrade Gordon, Patricia ^a   Eckardt, Annette J ^a   Conway, Bruce R ^b   Westover, Lori ^b   Xu, Jun Z ^b   Look, Richard ^b   Demarest, Keith T ^b   Emanuel, Stuart ^b   Maryanoff, Bruce E ^a  

^a Drug Discovery   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ANTINEOPLASTIC AGENT; BISINDOLYLMALEIMIDE; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; INTERLEUKIN 8; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C GAMMA; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE C ZETA; RUBOXISTAURIN; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; IC 50;

EID: 12444300117     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00644-9     Document Type: Article

References (32)

1. (a) Garcia-Echeverria C., Traxler P., Evans D.B. Med. Res. Rev. 20:2000;28.
2. (b) Sridhar R., Hanson-Painton O., Cooper D.R. Pharm. Res. 17:2000;1345.
3. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. Science. 298:2002;1912.
4. Goekjian P.G., Jirousek M.R. Curr. Med. Chem. 6:1999;877.
5. (a) Way K.J., Katai N., King G.L. Diabetes Med. 18:2001;945.
6. (b) Bullock W.H., Magnuson S.R., Choi S., Gunn D.E., Rudolph J. Curr. Top. Med. Chem. 2:2002;915.
7. (a) Embi N., Rylatt D.B., Cohen P. Eur. J. Biochem. 107:1980;519.
8. (b) Woodgett J.R. EMBO. J. 9:1990;2431.
9. (a) Grimes C.A., Jope R.S. Prog. Neurobiol. 65:2001;391.
10. (b) Kim H.-S., Skurk C., Thomas S.R., Bialik A., Suhara T., Kureishi Y., Birnbaum M., Keaney J.F. Jr., Walsh K. J. Biol. Chem. 277:2002;41888.
11. (c) Manoukian A.S., Woodgett J.R. Adv. Cancer Res. 84:2002;203.
12. (a) Kaidanovich O., Eldar-Finkelman H. Exp. Opin. Ther. Targets. 6:2002;555.
13. (b) Wagman A.S., Nuss J.M. Curr. Pharm. Des. 7:2001;417.
14. Eldar-Finkelman H. Trends Mol. Med. 8:2002;126 Dorronsoro I., Castro A., Martinez A. Exp. Opin. Ther. Pat. 2:2002;1527.
15. Eldar-Finkelman H. Trends Mol. Med. 8:2002;126 Dorronsoro I., Castro A., Martinez A. Exp. Opin. Ther. Pat. 2:2002;1527.
16. Goekjian P.G., Jirousek M.R. Exp. Opin. Invest. Drugs. 10:2001;2117.
17. (a) Sorbera L.A., Silvestre J., Rabasseda X., Castaner J. Drugs Future. 25:2000;1017.
18. (b) Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.-E., Kern T.S., Ballas L.M., Health L.E., Stramm L.E., Feener E.P., King G.L. Science. 272:1996;728.
19. (c) Jirousek M.R., Gillig J.R., Gonzalez C.M., Heath W.F., McDonald J.H. III, Neel D.A., Rito C.J., Singh U., Stramm L.E., Melikian-Badalian A., Baevsky M., Ballas L.M., Hall S.E., Winneroski L.L., Faul M.M. J. Med. Chem. 39:1996;2664.
20. (a) Martinez A., Castro A., Dorronsoro I., Alonso M. Med. Res. Rev. 22:2002;373.
21. (b) Cline G.W., Johnson K., Regittnig W., Perret P., Tozzo E., Xiao L., Damico C., Shulman G.I. Diabetes. 51:2002;2903.
22. (c) Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. J. Med. Chem. 45:2002;1292.
23. (d) Nikoulina S.E., Ciaraldi T.P., Mudaliar S., Carter L., Johnson K., Henry R.R. Diabetes. 51:2002;2190.
24. (e) Cross D.A.E., Culbert A.A., Chalmers K.A., Facci L., Skaper S.D., Reith A.D. J. Neurochem. 77:2001;94.
25. (f) Smith D.G., Buffet M., Fenwick A.E., Haigh D., Ife R.J., Saunders M., Slingsby B.P., Stacey R., Ward R.W. Bioorg. Med. Chem. Lett. 11:2001;635.
26. (g) Coghlan M.P., Culbert A.A., Cross D.A.E., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Cox L.R., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J.C. Chem. Biol. 7:2000;793.
27. (h) Ring D.B., Johnson K.W., Henriksen E.J., Nuss J.M., Goff D., Kinnick T.R., Ma S.T., Reeder J.W., Samuels I., Slabiak T., Wagman A.S., Hammond M.-E.W., Harrison S.D. Diabetes. 52:2003;588.
28. A paper on related macrocyclic polyoxygenated bis-7-azaindolylmaleimides as selective GSK-3β inhibitors was submitted for publication separately: G.-H. Kuo et al., J. Med. Chem. 2003.
29. Faul M.M., Winneroski L.L., Krumrich C.A. Tetrahedron Lett. 40:1999;1109.
30. Faul M.M., Winneroski L.L., Krumrich C.A., Sullivan K.A., Gillig J.R., Neel D.A., Rito C.J., Jirousek M.R. J. Org. Chem. 63:1998;1961.
31. Hers I., Tavare J.M., Denton R.M. FEBS Lett. 460:1999;433.
32. Grant E.R., Errico M.A., Emanuel S.L., Benjamin D., McMillian M.K., Wadsworth S.A., Zivin R.A., Zhong Z. Biochem. Pharmacol. 62:2001;283.